We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative risk of failure of ABC/3 TC or TDF/ FTC based first-line regimens in patients with a high viral load.
- Authors
Flandre, P; Pugliese, P; Allavena, C; Katlama, C; Cotte, L; Cheret, A; Cabié, A; Rey, D; Chirouze, C; Bani‐Sadr, F; Cuzin, L; Enel, P.; Obry‐Roguet, V.; Faucher, O.; Bregigeon, S.; Poizot‐Martin, I.; Marchou, B.; Massip, P.; Bonnet, E.; Obadia, M.
- Abstract
Objectives To compare the efficacy, in current clinical practice, of first regimens containing abacavir with lamivudine ( ABC/3 TC) or tenofovir with emtricitabine ( TDF/ FTC) in patients with baseline viral load ≥100 000 HIV-1 RNA copies/mL. Methods Using a prospective cohort, we selected all patients starting a first HIV regimen based either on ABC/3 TC or on TDF/ FTC. The propensity score ( PS) method was used to limit the indication bias due to the observational nature of the data. Adjusting and weighting methods via PS were used to compare the effectiveness of a first regimen containing ABC/3 TC or TDF/ FTC. The primary outcome was treatment failure by month 12 (M12). Results Overall, 2781 patients started an antiretroviral ( ARV) regimen with ABC/3 TC or TDF/ FTC each in combination with efavirenz, boosted atazanavir or boosted darunavir. Among the 2472 uncensored patients before M12, 962 (39%) had a baseline viral load ≥100 000 copies/ mL of whom 294 were in treatment failure at or before M12. Our analyses showed no difference between ABC/3 TC and TDF/ FTC in the risk of treatment failure at M12 in patients starting an ARV regimen with a high viral load (≥100 000 copies/ mL). Conclusions Using a large prospectively collected cohort of patients seeking care in France, we found no evidence that ABC/3 TC based regimens led to more failures than TDF/ FTC based ones in patients with high baseline viral loads.
- Subjects
FRANCE; EMTRICITABINE-tenofovir; DARUNAVIR; ATAZANAVIR; EFAVIRENZ; ABACAVIR-lamivudine (Drug); HIV; HIV infections; HIV-positive persons; LONGITUDINAL method; RNA viruses; VIRAL load; TREATMENT effectiveness; THERAPEUTICS
- Publication
HIV Medicine, 2016, Vol 17, Issue 5, p380
- ISSN
1464-2662
- Publication type
Article
- DOI
10.1111/hiv.12306